1 year follow Up results of “ARTIM HF TRIAL” (angiotensin receptor neprilysin inhibitor effect on TEI index & left ventricular mass in heart failure)

BACKGROUND: Sacubitril/Valsartan (ARNI) has now class 1 recommendation for treatment of heart failure with reduced ejection fraction (HFrEF). It has been shown to reduce cardiovascular morbidity & mortality in Heart failure with reduced ejection fraction (HFrEF) and significant improvement in al...

Descripción completa

Detalles Bibliográficos
Autores principales: Gokhroo, Rajendra Kumar, Anushri, Kaul, Tarik, M.T., Kailash, C., Rajesh, N., Ashish, K., Manish, G., Subhash, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065347/
https://www.ncbi.nlm.nih.gov/pubmed/33865519
http://dx.doi.org/10.1016/j.ihj.2021.01.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065347/
https://www.ncbi.nlm.nih.gov/pubmed/33865519
http://dx.doi.org/10.1016/j.ihj.2021.01.010

Ejemplares similares